EDCTP Alumni Network

Fostering excellence and collaboration in the next generation of researchers

Call EDCTP Clinical Research & Development Fellowship (R&D F)
Programme EDCTP2
Start Date 2020-02-01
End Date 2022-10-31
Project Code TMA2018IF-2484
Status Active


Infectious Diseases Data Observatory (IDDO), University of Oxford, United Kingdom


Training Plan Goal: To acquire advanced knowledge and skills in clinical trials design, data analysis and data sharing, operations for implementation of research action and development in Africa. Objectives • Gain skills in clinical trial design • Gain skills in statistics, sample size calculation and data analysis • Gain skills in protocol development and systematics reviews • Gain skills in online English course and have a direct contact with community of researchers • Enhance skills in clinical trial toolkits on antimalarial drug • Acquire skills in other relevant training opportunities

Host Organisation

Institution Country
University of Oxford United Kingdom

Study Design

During the fellowship in the host organization, I will carry out following activities: • English courses • Training on clinical trials design at IDDO • Training on statistics, sample size calculation and data analysis at IDDO • Training on protocol development and systematics reviews at IDDO • Training on clinical trial toolkits on antimalarial drug at IDDO • Training on other relevant training opportunities at IDDO(e.g: Database design, introduction to R and Stata, Geospatial analysis using ArcGIS etc) • Training modules on good practice in data management, ethics data and anti-malaria toolkits of IDDO

Current Organisation

Infectious Diseases Data Observatory, University of Oxford

Current Job Title

EDCTP-Fellow/ Visiting Researcher


2018 TMA2018IF-2484

Students Supervised

Type Name Title University Start Date End Date


Role Committee/board Start Date End Date
Reporter Institutional Ethic Committee of INSP 2021 2024


Institution Degree Year
Universite Joseph KI ZERBO, Burkina Faso PhD 2020-10-08
Universite Joseph KI ZERBO, Burkina Faso MSc 2011-07-14
Universite Joseph KI ZERBO, Burkina Faso Licence 2007-09-30

Areas Of Specialisation




Evidence-Based Complementary and Alternative Medicine
Up to now, the control of malaria remains a challenge. The World Health Organization (WHO) recommends the use of artemisinin-based combination therapies (ACTs) for uncomplicated malaria treatment. Despite this guideline, many people in Burkina Faso use herbal medicine as primary treatment against malaria. The aim of this study was to assess the in vivo activity of Guiera senegalensis J. F. Gmel and Bauhinia rufescens Lam. leaves extracts against Plasmodium berghei ANKA. A four-day treatment of leaves decoction of each plant was administrated orally to 7 groups of six NMRI (Naval Medical Research Institute) mice infected with Plasmodium berghei ANKA strain. The control group received distilled water as treatment while the treated groups each received daily 100, 250, and 500 mg extract/kg body weight. Thin blood smears were performed on day five and the percentage of reduction of parasitaemia was determined compared to the control. The percentages of reduction of the parasitaemia at the doses of 100, 250, and 500 mg extract/kg body weight were, respectively, 57.5%, 35.9%, and 44.9% for Guiera senegalensis and 50.6%, 22.2%, and 25.7% for Bauhinia rufescens. Our findings on antiplasmodial activity of these two plants justify the traditional use by local populations against malaria. Thus, the isolation of the active compounds from these two plants is suggested for possible antimalarial candidate drugs.
SIRIMA Sodiomon Bienvenu , Groupe de Recherche Action en Santé (GRAS), 06 BP 10248 Ouagadougou 06 Burkina Faso.
Academic Journal: African Journal of Pharmacy and Pharmacology

In the crude extracts of the bark and leaves of Sclerocarya birrea, have been characterized sterols,
triterpenes, saponosides, tannins, anthocyanosides, coumarins, reducing compounds, alkaloids and
carotenoids. Tests were carried out in vitro with extracts from each part of the plant to assess their
efficacy against strains of Plasmodium falciparum sensitive to chloroquine K1 and that resistant to
chloroquine 3D7. The crude alkaloidal extracts of the bark gave IC50 = 2.54 μg / ml with the strain 3D7
and an IC50 = 4.09 μg / ml with the strain K1. On the other hand, the extracts with CH2Cl2 showed an
IC50 = 36.59 and 37.78 μg / ml respectively with the 3D7 and K1 strains. Those with CH3OH gave IC50 all
greater than 50 μg/ml with both strains. The CH3OH / H2O extracts gave IC50 = 21.48 μg / ml with the K1
strain and greater than 50 μg / ml with 3D7. As for the H2O extracts, the IC50 were = 11.43 μg / ml with
the K1 strain and also greater than 50 μg / ml with the 3D7. The alkaloid extracts of leaf gave an IC50 =
9.68 μg / ml with 3D7 and = 3.56 μg / ml with strain K1. With CH2Cl2, and IC50 = 6.62 μg / ml was obtained
with 3D7 and 4.05 μg / ml with strain K1. The CH3OH extracts gave an IC50 = 21.12 μg / ml with the 3D7
strain and 21.06 μg / ml with the KI strain. The CH3OH / H2O extracts gave with strain 3D7 and IC50 of
more than 50 and 32.73 μg / ml with K1. The aqueous extracts gave IC50 greater than 50 μg / ml for 3D7
and 25.17 μg / ml with the K1 strain.

SCHOLARENA www.scholarena SAJ Pharmacy and Pharmacology


Send a Message